Teresa attended Universidad Complutense de Madrid, where she earned her Pharm.D. She then moved to the US to complete a PhD in Anatomy and Neurobiology at Boston University. Following her dissertation on cortical development, she joined the Lopez-Bendito lab to explore the role of spontaneous activity in the emergence of cortical sensory modalities. Passionate about circuits, she is seeking to understand how neuronal networks integrate with glia during normal development and in brain cancer. 

Pedro received his Master's degree in Biotechnology from Boston University in January 2022. He worked in the lab of Prof. Hengye Man, where he investigated the neurobiology of Autism Spectrum Disorder. After graduating, he joined Rgenta Therapeutics, a company developing RNA-targeting small molecules. His work focused on studying the molecular basis behind repeat expansion disorders and developing novel assays and cellular disease models to profile novel therapeutics. Pedro joined the Guillamon-Vivancos Lab as a PhD student in April 2026 to explore neuro-glial calcium signaling dynamics in development and its disruption in brain tumors.

Isabel joined the López-Bendito lab in 2025, where she carried out her Master’s research project. Her work focused on investigating the role of teneurins and other cell-adhesion molecules in sensory modality specification during cortical development. Following graduation, she received funding (FPU) to pursue a PhD under the joint supervision of Guillermina López Bendito and Teresa Guillamón Vivancos. Her current research aims to identify the gene regulatory networks underlying thalamocortical sensory-modality specification and to determine how activity-related genes contribute to cortical sensory identity during development.

Francisco Javier trained as a Clinical and Biomedical Laboratory Technician before completing his Bachelor’s degree in Biology at Universidad Autónoma de Madrid, where he developed a strong interest in genetics, molecular biology and cell biology. During his undergraduate training, he worked at IMDEA Food Institute on projects involving murine models of healthy ageing and venom-derived peptides as potential therapeutic agents against melanoma, contributing as a co-author to a publication in Cell Death & Discovery. He joined the lab in 2026 as a research technician working with mouse models, supporting colony management, sample collection and SPF animal work. His current interests include biomedical research, cancer biology and experimental models of disease.